Invesco Variable Rate Preferred ETF (VRP)

Nói về

Verona Pharma plc is the United Kingdom-based biotechnology company. The principal activity of the company is the development of novel, first-in-class drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cough. The Company’s operating segments include clinical and basic research. The Company operates in two geographical segments: the United Kingdom and Canada. The Company’s product pipeline focuses on research, discovery and development of new therapeutic drugs for the treatment of chronic respiratory diseases. At present there are three products: RPL554, VRP7 and NAIPs. RPL554 and VRP7 are in the clinical phase, RPL554 having successfully completed Phase 1 and 2 trials, VRP7 having successfully completed a Phase 2 trial, and NAIPs are in the basic research phase. The Company currently has one wholly owned subsidiary, Rhinopharma Limited.